compounded semaglutide weight loss effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Semaglutide: A Retrospective Comparative Study The FDA's Decision to Ban

Anyone considering treatment with an FDA-approved GLP-1/GIP therapy like tirzepatide should do so only under the guidance of a licensed healthcare provider, who can evaluate individual health history, monitor for side effects, and adjust dosing appropriately

The FDA has previously cautioned about the risks associated with compounded drugs, especially during shortages like that of semaglutide

Body mass index and the risk of rheumatic disease: linear and nonlinear Mendelian randomization analyses

Consumers should be wary of dietary supplements claiming to contain GLP-1 or promising "GLP-1-like" effects, as these claims are not FDA-approved and lack scientific validity